Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] Hop Tenon, Serv Oncol Med & Therapie Cellulaire, 4 Rue Chine, F-75020 Paris, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
[4] PSL Res Univ, Inst Curie, INSERM, U830, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2020年 / 107卷 / 11期
关键词：
POSITIVE SOLID TUMORS;
D O I：
10.1016/j.bulcan.2020.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / +
页数：2
相关论文
共 50 条
  • [31] Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
    Ardini, Elena
    Siena, Salvatore
    ESMO OPEN, 2020, 5 (05)
  • [32] Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
    Lassen, Ulrik
    LANCET ONCOLOGY, 2020, 21 (02): : 193 - 194
  • [33] Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
    Lu, J.
    Blakely, C. M.
    Barve, M.
    Chung, C. H.
    Waqar, S. N.
    Hu, X.
    Delord, J-P.
    Krzakowski, M. J.
    Yonemori, K.
    Chen, D. T.
    Klingbiel, D.
    Heinzmann, S.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S204 - S205
  • [34] Entrectinib: First Global Approval
    Zaina T. Al-Salama
    Susan J. Keam
    Drugs, 2019, 79 : 1477 - 1483
  • [35] Challenges in the Diagnosis of NTRK Fusion-Positive Cancers
    Gautschi, Oliver
    Bubendorf, Lukas
    Leyvraz, Serge
    Menon, Roopika
    Diebold, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (07) : E107 - E109
  • [36] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Bazhenova, L.
    Liu, S. V.
    Lin, J. J.
    Lu, S.
    Drilon, A.
    Chawla, S. P.
    Fakih, M.
    Krzakowski, M.
    Paz-Ares, L.
    Blakely, C.
    Buchschacher, G. L., Jr.
    Cassier, P.
    Fan, Y.
    Folprecht, G.
    McCallum, S.
    Pitcher, B.
    Chen, D.
    Freund, R.
    Springfeld, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
  • [37] Larotrectinib: First Global Approval
    Scott, Lesley J.
    DRUGS, 2019, 79 (02) : 201 - 206
  • [38] Larotrectinib: First Global Approval
    Lesley J. Scott
    Drugs, 2019, 79 : 201 - 206
  • [39] Progression free survival of larotrectinib in patients with NTRK fusion-positive tumors: a systematic review
    Sumampow, M. M. A.
    Fu, R. C. E.
    Delvino, D.
    Albert, N.
    Danisha, P. A. C.
    Satcitta, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1353 - S1353
  • [40] Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
    Grogan, Patrick T.
    Deming, Dustin A.
    Helgager, Jeffrey
    Ruszkiewicz, Theresa
    Baskaya, Mustafa K.
    Howard, Steven P.
    Robins, H. Ian
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
12345